Fierce Pharma June 24, 2024
Following Novo Nordisk’s recent Wegovy approval to cut heart risks in adults with obesity, Eli Lilly appears to be homing in on the next potential label expansion for its rival GIP/GLP-1 weight-loss med Zepbound.
Late last week, Lilly shared detailed results from its phase 3 SURMOUNT-OSA study, which found that Zepbound at the 10 mg and 15 mg doses aced all primary and secondary endpoints in obese patients with obstructive sleep apnea (OSA), both with or without positive airway pressure (PAP) therapy.
Investigators published the data in The New England Journal of Medicine and presented the full results at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida, on Friday.
Zepbound, also known as tirzepatide, won its initial nod...
Today's Sponsors
Today's Sponsor